Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

20,010.00
31 May 2016
Change (% chg)

-- (--)
Prev Close
20,010.00₪
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
501,079
52-wk High
27,590.00₪
52-wk Low
18,940.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 1.04
Market Cap(Mil.): ₪204,596.09
Shares Outstanding(Mil.): 1,022.26
Dividend: 130.86
Yield (%): 2.70

Financials

  TEVA.TA Industry Sector
P/E (TTM): 27.07 34.86 35.86
EPS (TTM): 7.39 -- --
ROI: 4.98 14.00 13.34
ROE: 6.40 15.11 14.59

FDA asks Teva Pharmaceutical for further study on Huntington's drug

JERUSALEM Approval for Israel-based Teva Pharmaceutical Industries' drug to treat the neurological disorder chorea has been held up by U.S. regulators seeking further blood studies, the company said on Tuesday.

May 31 2016

UPDATE 1-FDA asks Teva Pharmaceutical for further study on Huntington's drug

JERUSALEM, May 31 Approval for Israel-based Teva Pharmaceutical Industries' drug to treat the neurological disorder chorea has been held up by U.S. regulators seeking further blood studies, the company said on Tuesday.

May 31 2016

FDA asks Teva Pharmaceutical for further study on Huntington drug

JERUSALEM, May 31 Israel-based Teva Pharmaceutical Industries said on Tuesday approval for a drug to treat chorea stemming from Huntington disease (HD) has been held up by U.S. regulators seeking further blood study.

May 31 2016

BRIEF-Teva Pharmaceutical receives complete response letter for SD-809

* FDA has asked Teva to examine blood levels of certain metabolites

May 31 2016

BRIEF-Spectrum Pharma says unit, Teva enter settlement agreement

* Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn

May 25 2016

Allergan CEO says company is 'weeks away' from closing Teva deal

Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

Allergan CEO says company is 'weeks away' from closing Teva deal

NEW YORK Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

UPDATE 1-Allergan CEO says company is "weeks away" from closing Teva deal

NEW YORK, May 23 Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

Allergan CEO says company is "weeks away" from closing Teva deal

May 23 Allergan Inc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

May 23 2016

BRIEF-Allergan CEO says company is "weeks away" from closing Teva deal

* Allergan CEO says company is free to do multibillion dollar deals after Teva transaction closes

May 23 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : GlobalData
$300.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.